AUTHORS
Uday Aditya Sarkar, PhD, Kiyomi Mashima, MD, PhD2, Roberta Azevedo, MD3, Stacey M. Fernandes, BS4, Ayazhan Umutbayeva, MD5, Colin McNulty6, Mariia Mikhaleva, MD7, Ava Bidgoli8, Paulina Predko, BS9, Jennifer R. Brown, MD, PhD10, Paolo Ghia, MD, PhD11
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
11 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States, IRCCS Ospedale San Raffaele, Milano, Italy, Università Vita-Salute San Raffaele, Milano, Italy
ABSTRACT
Introduction
Monoclonal serum immunoglobulin (M-spike) is prevalent in chronic lymphocytic leukemia (CLL), but its independent clinical and biological impact remains poorly characterized. We aimed to retrospectively evaluate the clinical and genomic correlates of M-spike and its independent prognostic impact in a single center cohort of CLL patients treated at the Dana-Farber Cancer Institute (DFCI).
Methods
We analyzed 1,294 CLL patients from the DFCI database diagnosed between 2013-2023 with available baseline serum protein electrophoresis/immunofixation and integrated cytogenetic, molecular and clinical data. Patients were stratified by presence or absence of M-spike and evaluated in terms of baseline clinical-genomic features and clinical outcomes. Time to first treatment (TTFT) and overall survival (OS) were analyzed using Kaplan-Meier methods with Bonferroni correction for multiple comparisons. Univariable and multivariable Cox proportional hazards models, restricted to 893 patients with complete baseline covariate data, were utilized to assess the independent prognostic value of M-spike alongside standard high-risk features, including TP53 aberrations and complex karyotype (CK, defined as 3 abnormalities).
Results
Among 1,294 evaluated patients, 247 (19.1%) presented with an M-spike. The presence of M-spike was significantly associated with older median age at diagnosis (64.1 vs 62.2 years, p=0.035) and male gender (66.0% vs 58.5%, p=0.036). Genomically, the M-spike cohort was highly enriched for high-risk and distinct cytogenetic features, including TP53 abnormalities (25.1% vs 11.8%, p<0.0001), del(17p) (21.2% vs 7.1%, p<0.0001), and trisomy 12 (30.2% vs 19.5%, p<0.0001). The presence of an M-spike was not found to be significantly associated with unmutated IGHV status (50.2% in M-spike vs 45.2% in non-M-spike cohort, p=0.18). Among M-spike subclasses, IgG (n=113; median 0.27 g/dL, range unquantifiable to 1.84) and IgM (n=94; median 0.17 g/dL, range unquantifiable to 2.85) predominated. IGH locus (14q32) abnormalities were significantly more frequent in the IgG subgroup compared to the IgM subgroup (9.7% [6 rearrangements, 5 deletions] vs 2.1% [2 rearrangements, 0 deletions], p=0.040). Conversely, in the subset with available targeted sequencing, MYD88 mutations were exclusively found in the IgM subgroup and absent in the non-IgM M-spike cases (13.9% [5/36] vs 0% [0/51], p=0.011).
Clinically, M‑spike was associated with significantly shorter TTFT (40.1 vs 70.7 months, p<0.0001) and inferior OS (p<0.0001) compared to those without a M-spike, with no significant difference in TTFT among the M-spike subgroups (IgM 37.4 months, IgG 40.1 months; p=1.00). In multivariable models, the presence of M-spike remained an independent adverse predictor for TTFT (HR 1.54, 95% CI 1.23-1.94, p<0.0001), independent of other significant variables such as unmutated IGHV (HR 2.88, 95% CI 2.32-3.58, p<0.0001), TP53 abnormalities (HR 1.38, 95% CI 1.07-1.76, p=0.012), and CK≥3 (HR 1.49, 95% CI 1.16-1.91, p=0.002).
Risk stratification integrating M-spike, TP53, and CK status revealed a compounding adverse effect. Compared to the baseline-risk cohort with neither M-spike nor high-risk features, the presence of M-spike alone independently increased the risk of early treatment (HR 1.68, p < 0.0001). For patients harboring both a TP53 aberration and CK≥3 without a M-spike, the risk of early treatment was elevated (HR 3.07, 95% CI 2.20-4.29, p<0.0001). This risk was profoundly magnified when a M-spike was also present (HR 5.75, 95% CI 3.92-8.43, p<0.0001). Notably, we identified an ultra-high-risk subset harboring M-spike, TP53 abnormality, and highly complex karyotype (CK≥5), which demonstrated an exceptionally short median TTFT of 6.7 months.
Conclusion
In this large CLL cohort, M‑spike identifies a distinct, biologically enriched high‑risk subset characterized by older age, adverse cytogenetics, and significantly shorter TTFT, a trend particularly pronounced in the IgM subtype. M‑spike remains independently prognostic after adjustment for established markers and amplifies risk when combined with CK and TP53 aberrations. The specific enrichment of 14q32 locus abnormalities in the cases of the IgG subgroup likely reflects class switch events. Further investigations are warranted to validate these compounding risk models and to define optimal therapeutic strategies for the high-risk subset identified by M-spike, TP53 abnormalities, and CK.
DISCLOSURES
Uday Aditya Sarkar, PhD: No relevant conflicts of interest to declare.